Trevi Therapeutics Inc (TRVI)

Trevi Therapeutics Announces Upcoming June and July Event Schedule  

NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage...

Form 8-K - Current report

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway...

Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference

Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with...

Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026

NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a...

Trevi Therapeutics to Participate in Upcoming May Events

NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a...

Form DEF 14A - Other definitive proxy statements

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report